ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Cipla Ltd.

Company Background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

Business Summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2020 INRUSD
Gross Profit53,964.60M761.07M
Operating income19,122.50M269.68M
Income before tax21,781.80M307.19M
Net income15,465.20M218.10M
Diluted EPS19.160.27
Dividends Per Share----
Total Assets236,625.60M3,127.84M
Total liabilities75,963.70M1,004.13M
Total equity157,630M2,083.64M
Operating cash flow29,550.80M416.76M
Currency in INRCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 134,420.40M 142,298.10M 150,110.30M 161,887.40M 168,571.40M
Gross Profit 46,429.40M 48,235.70M 52,774.30M 51,888.70M 53,964.60M
Operating income 17,463.70M 15,212M 17,775.30M 18,901.50M 19,122.50M
Income before tax 17,270.30M 12,221.70M 16,694.60M 20,791.40M 21,781.80M
Net income 13,599.90M 10,063.90M 14,105.30M 15,277M 15,465.20M
EBITDA 25,005.50M 23,926.60M 27,273.40M 29,858.10M 30,095.60M
Diluted EPS 16.89 12.50 17.50 18.93 19.16
Dividends Per Share 2 2 3 3 --
Total Assets 211,281.80M 210,370.70M 228,605.50M 239,633.20M 236,625.60M
Total liabilities 92,449.70M 80,411.30M 82,633.90M 86,090.80M 75,963.70M
Total equity 115,162.20M 125,436.60M 142,291.90M 150,122.80M 157,630M
Operating cash flow 15,885.70M 22,344.50M 13,781.60M 16,047.80M 29,550.80M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 2,053.13M 2,122.04M 2,328.51M 2,314.57M 2,377.39M
Gross Profit 709.16M 719.32M 818.63M 741.87M 761.07M
Operating income 266.74M 226.85M 275.73M 270.24M 269.68M
Income before tax 263.78M 182.25M 258.96M 297.26M 307.19M
Net income 207.72M 150.07M 218.80M 218.42M 218.10M
EBITDA 381.93M 356.80M 423.06M 426.89M 424.44M
Diluted EPS 0.25 0.18 0.27 0.27 0.27
Dividends Per Share 0.03 0.02 0.04 0.04 --
Total Assets 3,190.48M 3,239.71M 3,505.05M 3,459.15M 3,127.84M
Total liabilities 1,396.04M 1,238.33M 1,266.96M 1,242.73M 1,004.13M
Total equity 1,739.01M 1,931.72M 2,181.66M 2,167.05M 2,083.64M
Operating cash flow 242.63M 333.21M 213.78M 229.44M 416.76M

Valuation Measures

Mar 2020
Operating margin11.34%
Profit margin9.17%

Key executives

  • Chief Executive Officer, MD & Director: Umang Vohra
  • President & Global Chief People Officer: Raju Mistry
  • Global Chief Financial Officer: Kedar Upadhye
  • Global Chief Medical Officer: Jaideep A. Gogtay
  • President-Global Quality & Medical Affairs: Ranjana Pathak


  • AHMED SOPHIE (5.7%)
  • SBI Funds Management Pvt Ltd. (2.8%)
  • ICICI Prudential Asset Management Co. Ltd. (2.5%)
  • Life Insurance Corp of India (1.7%)
  • Norges Bank Investment Management (1.6%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (1.6%)
  • The Vanguard Group, Inc. (1.6%)

Contact Details

  • Website:
  • Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Mumbai, 400013, India
  • Phone: +91.22.24826000

Related Companies

  • CIpla Ilac TIcaret AS
  • Madison Pharmaceuticals, Inc.
  • Cipla Gulf FZ LLC
  • Cipla Technologies LLC
  • Cipla BioTec South Africa (Pty) Ltd.
  • Cipla Philippines, Inc.
  • Cipla Middle East Pharmaceuticals FZ LLC
  • Medica Pharmaceutical Industries Co. Ltd.
  • Breathe Free Lanka Pvt Ltd.
  • Cipla Medpro Botswana Pty Ltd.
  • Cipla Medpro Distribution Centre Pty Ltd.
  • Cipla Life Sciences Pty Ltd.
  • Cipla Dibcare Pty Ltd.
  • Cape to Cairo Exports Pty Ltd.
  • Cipla Medpro Holdings Pty Ltd.
  • Cipla Malaysia Sdn. Bhd.
  • Cipla Kenya Ltd.
  • Cipla Australia Pty Ltd.
  • Cipla (Mauritius) Ltd.
  • Sitec Labs Ltd.
  • Wanbury Ltd. /4 Brands/
  • AJM Pharma (Pvt) Ltd.
  • Goldencross Pharma Pvt Ltd.
  • Cipla Europe NV
  • Inyanga Trading 386 (Pty) Ltd.
  • Cipla USA, Inc.
  • Meditab Holdings Ltd.
  • Quality Chemicals Ltd.
  • Jay Precision Pharmaceuticals Pvt Ltd.
  • Medispray Laboratories Pvt Ltd.


  • Dr. Reddy's Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc. Class A
  • Adcock Ingram Holdings Limited
  • Knight Therapeutics, Inc.
  • Aurisco Pharmaceutical Co. Ltd. Class A
  • Iterum Therapeutics plc
  • Spero Therapeutics, Inc.
  • Anupam Rasayan India Ltd.
  • Aurobindo Pharma Ltd
  • Amphastar Pharmaceuticals Inc
Last Updated on 19 Apr, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more